EVAN (39) showed that in patients with stage IIIA NSCLC with R0 resection and a sensitive EGFR gene mutation, postoperative targeted therapy with erlotinib can benefit patients more than can chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.